Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) FCF Margin (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of FCF Margin data on record, last reported at 7047.5% in Q3 2025.

  • For Q3 2025, FCF Margin fell 469204.0% year-over-year to 7047.5%; the TTM value through Sep 2025 reached 5427.64%, down 197225.0%, while the annual FY2024 figure was 4199.06%, 124492.0% down from the prior year.
  • FCF Margin reached 7047.5% in Q3 2025 per NWBO's latest filing, down from 5337.4% in the prior quarter.
  • Across five years, FCF Margin topped out at 1428.64% in Q1 2023 and bottomed at 8770.13% in Q4 2024.
  • Average FCF Margin over 5 years is 4202.89%, with a median of 3407.0% recorded in 2023.
  • Peak YoY movement for FCF Margin: skyrocketed 37665505bps in 2021, then crashed -518568bps in 2022.
  • A 5-year view of FCF Margin shows it stood at 2772.57% in 2021, then skyrocketed by 33bps to 1844.05% in 2022, then plummeted by -112bps to 3904.72% in 2023, then tumbled by -125bps to 8770.13% in 2024, then grew by 20bps to 7047.5% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 7047.5% in Q3 2025, 5337.4% in Q2 2025, and 2536.27% in Q1 2025.